Bli medlem
Bli medlem

Du är här

2016-05-17

Immunicum AB: Immunicum Engages US Based Accelovance and the Midwest Melanoma Partnership (MMP) to Evaluate INTUVAX and to Advance the Clinical Studies Pipeline

Gothenburg, Sweden, May 17, 2016 - Immunicum AB (publ), pursuing to develop
sophisticated, safe and efficient therapeutic cancer treatments with powerful
and long lasting immune responses, today announced the establishment of a
clinical development services agreement with Accelovance to advance the
Company's lead cancer immune primer, INTUVAX, into the US in kidney cancer
and in melanoma. Through this agreement, Accelovance, a
Contract Research Organization (CRO),
will support Immunicum's clinical development strategies by offering
scientific, medical and regulatory expertise, in addition to providing
support through Project Management, Clinical Monitoring, Data Management,
Biostatistics, and Safety services for Immunicum's clinical trials in the US.
The agreement will also provide access to Accelovance's Preferred Sites
Network via their association with the US Based non-profit, Midwest Melanoma
Partnership (MMP).
Lead Investigator in the US,
Dr. Arkadiusz Dudek, Director of the Oncology Clinical Trials Office at the
University of Illinois' College of Medicine, has many years of experience in
immuno-oncology and has previously conducted clinical trials in kidney cancer
and melanoma.

"This partnership will bring together an extraordinary team and ample
resources to advance and expedite the development of INTUVAX and Immunicum's
clinical advancement in the United States", said Jamal El-Mosleh, CEO of
Immunicum. El-Mosleh continued, "We believe we have found the best
collaboration scenario to aid us with our company's next step in clinical
development. This new agreement underscores our commitment to researching the
effectiveness of INTUVAX as a cancer immune primer in additional indications
and expands our research capabilities tremendously. We are very excited to
have Dr. Dudek as our Lead Investigator for the MERECA-trial in the US and
for the melanoma trial in the US. His expertise in heading up laboratory
research on cancer microenvironment, angiogenesis, cancer vaccines and
preclinical novel drug testing, along with the solid experience of
Accelovance and the MMP, makes moving forward possible".

Under the agreement, Immunicum will maintain oversight and quality standards
relating to patient safety and regulatory compliance, with Accelovance
assisting with the development and implementation of clinical strategies.
Immunicum will rely on Accelovance's knowledge in the areas of vaccines,
oncology, and clinical management. Providing advanced insight into
Immunicum's development pipeline will enable both organizations to enhance
operational planning, consistency, and execution.

Arkadiusz Dudek, MD, Director of the Oncology Clinical Trials Office at the
University of Illinois' College of Medicine, will be the Lead Investigator on
both the MERECA (MEtastatic REnal cell CArcinoma) Trial and the US Melanoma
Trial, slated to begin later this year. Dr. Dudek's clinical interests
include phase I and II clinical trials in solid tumors; pancreatic cancer,
malignant melanoma, kidney cancer, and thoracic malignancies, and high dose
interleukin-2 program.

"We are extremely excited to enter into this partnership with Immunicum.
INTUVAX has stimulated significant interest with Accelovance as well as with
the Lead Investigator, Arkadiusz Dudek, MD. Combined with our strategic
experience and our alliance with the Midwest Melanoma Partnership, we will be
able to further enhance the research and advancement of treatment options for
cancer patients. It is a win-win for everyone," said Accelovance's Chief
Science Officer, Jamie Oliver, Pharm.D.

For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com

The Company's Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31.www.redeye.se

About INTUVAX

INTUVAX is a cancer immune primer, developed for the treatment of solid
tumors. Its active ingredient is activated white blood cells, so called
dendritic cells, derived from healthy blood donors. Intratumoral injection of
these cells is expected to lead to an inflammatory response which in turn
leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.

About Accelovance

Accelovance, Inc., headquartered in Rockville, MD, is an industry
award-winning global Contract Research Organization (CRO) focused primarily
in vaccine, oncology, and general medicine clinical research. As a clinical
services provider to the pharmaceutical and biotechnology industries,
Accelovance offers comprehensive clinical development services including
management and implementation of Phase I-IV clinical trials, supportive
research centers, and a clinical engagement solution utilized for
recruitment, post-marketing surveillance, and long-term survival follow-up.

For more information, please visitwww.accelovance.com

About the Midwest Melanoma Partnership (MMP)

The Midwest Melanoma Partnership (MMP) is a Multi-Institutional collaboration
of physicians, scientists and patient advocates dedicated to the development
of improved therapies for patients with malignant melanoma. Composed of 19
member organizations well known within the academic and community research
field (http://www.midwestmelanoma.org/?page_id=39), member organizations work
within their institution and across MMP membership institutions to
participate in clinical trials to advance treatment options for patients
diagnosed with melanoma.

For more information, please visitwww.midwestmelanoma.org.

About Immunicum AB (publ)

Immunicum AB (publ) is working to develop and advance cancer immune primers
for the treatment of tumor diseases. A clinical phase II trial for the
Company's most advanced product - INTUVAX® against kidney cancer - has been
initiated. The project portfolio contains additional clinical phase I/II
studies in liver cancer and in gastrointestinal stromal tumors (GIST).

For more information, please visitwww.immunicum.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

HUG#2013174

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.